July 1st 2025
The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
View More
Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma
View More
Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights
View More
Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
View More
Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer
View More
Palliative Care in HSCT Correlates With Longer Survival in Hematologic Cancers
June 14th 2023A retrospective analysis of more than 17,000 patients with hematologic malignancies identified a difference in median survival between patients who received palliative care in addition to hematopoietic stem cell transplantation and those who didn’t.
Ruxolitinib Appears to Yields Superior Responses in Polycythemia Vera Subtype
May 18th 2023Findings from the phase 2 MAJIC-PV trial highlight a superior event-free survival and overall survival following ruxolitinib vs best available treatment in patients with polycythemia vera who were intolerant/resistant to hydroxycarbamide.
FDA Accepts Supplemental NDA for Avapritinib in Indolent Systemic Mastocytosis
January 24th 2023Data from the phase 2 PIONEER trial supports the supplemental new drug application for avapritinib in adult patients with indolent systemic mastocytosis, an uncontrolled proliferation and activation of mast cells.
Unmet Social Needs May Worsen QOL Among Hematologic Cancer Survivors
January 23rd 2023An expert from Augusta University says cancer care should extend beyond treatment and highlights why unmet social needs should be a consideration for survivors of hematologic cancer, especially those with a lower socioeconomic status or who are of a racial or ethnic minority.